Clinical observation on Lamivudine combination Interferon treatment patients with chronic hepatitis B

Objective: To observe the effect of Lamivudine combination Interferon in the treatment of patients with chronic hepatitis B. Methods: 150 patients with chronic hepatitis B were divided into 3 groups, each group had 50 patients. The patients in combination group received Lamivudine and Interferonα-2b therapy for one year, the patients in lamivudine group and interferon group received lamivudine and interferonα-2b therapy respectively for one year. Results: After one year, the HBVDNA loss and HBeAg/anti-HBe seroconversion in combination group were 86% and 48%, respectively. They were higher than in Lamivudine group and Interferon group (P0.05), YMDD mutations were detected in one patients in combination group (2%), but 8 patients in Lamivudine group (16%). Conclusion: Lamivudine combination Interferon in the treatment of patients with chronic hepatitis B get a better effect and decrease YMDD mutation.